Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 16/20 | 0.52 |
| ▸ | AVPR2 | P30518 | 6/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.52 |
| ▸ | OXTR | P30559 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20728080 | 0.94 | AVPR1A (0.53) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL20728152 | 0.91 | AVPR1A (0.56) | AVPR1AAVPR2OXTR | |
| SCHEMBL20727976 | 0.88 | AVPR1A (0.61) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL20728002 | 0.88 | AVPR1A (0.47) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL20728013 | 0.88 | AVPR1A (0.47) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL20727733 | 0.87 | OXTR (0.58) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL20728280 | 0.86 | AVPR1A (0.49) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL20728531 | 0.86 | AVPR1A (0.53) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL20727789 | 0.86 | AVPR1A (0.47) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL20728144 | 0.85 | AVPR1A (0.55) | AVPR1AAVPR2KCNH2OXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858943-B2 | Vasopressin receptor antagonists and products and methods related thereto | Neumora Therapeutics, Inc. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11186577-B2 | Vasopressin receptor antagonists and products and methods related thereto | BLACKTHORN THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190048013-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Neumora Therapeutics, Inc. | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11186577-B2 | Vasopressin receptor antagonists and products and methods related thereto | AVPR1B, AVPR1A, AVPR2 | AVPR1A 2/4885AVPR2 3/4885KCNH2 635/4885 |
| US-20190048013-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | AVPR1B, AVPR1A, AVPR2 | AVPR1A 2/4885AVPR2 3/4885KCNH2 635/4885 |
| US-11858943-B2 | Vasopressin receptor antagonists and products and methods related thereto | AVPR1B, AVPR1A, AVPR2 | AVPR1A 2/4885AVPR2 3/4885KCNH2 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.